PUBLISHER: Orion Market Research | PRODUCT CODE: 1159241
PUBLISHER: Orion Market Research | PRODUCT CODE: 1159241
Global Heterozygous Familial Hypercholesterolemia Drugs Market Size, Share & Trends Analysis Report By Type (Gemcabene Calcium, MGL-3196, ST- 103 and Others), And By Application (Hospital, Medical Center, Clinics and Others) Forecast 2022-2028
The global heterozygous familial hypercholesterolemia drug market is anticipated to grow at a CAGR during the forecast period. In the year 2020, heterozygous familial hypercholesterolemia affects 30 million people worldwide. This disease is mainly observed by high levels of low-density lipoprotein cholesterol. This condition usually arises right from birth. Major cases of heterozygous familial hypercholesterolemia occur due to variants in the gene which encode LDL receptors. A high level of LDL cholesterol increases the risk of atherosclerotic cardiovascular disease. LDL cholesterol levels can be reduced by consistent use of PCSK9 synthesis. For instance, in Feb 2020, Michigan-based Esperion's drug got approval from FDA which can be used as a non-statin cholesterol-lowering medication. The drug is named Nexlitol. This drug is at par in treatment as other drugs in cholesterol-lowering such as PCSK9.
The global heterozygous familial hypercholesterolemia drug market is segmented based on type and application. Based on type, the market is segmented into Gemcabene Calcium, MGL-3196, ST- 103, and Others. Based on application the market is sub-segmented into hospitals, Medical Center, Clinics, and Others. Among these, the hospital segment is anticipated to grow at a widespread rate during the forecast period. Diagnosis of such disease requires examination of blood, liver, kidney, and other variables. Health experts make sure that body variables are on a normal level to prescribe medications and further diagnosis. Body checkups are done in the hospital facility and prescription is done on that basis. For instance, in May 2021, Verve Therapeutics announced that it had worked upon gene editing medicines, and it will bring the publication of proof of data concept highlighting it which is for the treatment of cardiovascular disease. This is published in the Journal Nature. This study discusses the lowering of low-density lipoprotein cholesterol.
Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific is going to be a good market for heterozygous familial hypercholesterolemia drugs. In the past few years, the trend of the high cholesterol issue has been shifted to the Asia region from western countries as the consumption of beef and red meat has increased in these regions. Genetics are also responsible for increasing cholesterol problems in these regions. For instance, in June 2020, as per an article published in the journal Nature, examination of blood for 102.6 million people from all over the world. It was found that level of cholesterol was high in people of the middle-income group in Asia as compared to the high-income group in western countries.
The major companies serving the global heterozygous familial hypercholesterolemia drug market include Daewoong Corp.Ltd., Esperion Therapeutics, Inc., Gemphire Therapeutics, Inc., Madrigal Pharmaceuticals Inc., AbbVie Inc., and others. For instance, in April 2021, Praluent (alirocumab) was approved by FDA for lowering cholesterol levels in patients who have familial hypercholesterolemia.
Research Methodology
The market study of the global Heterozygous familial hypercholesterolemia drug market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include:
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
The Report Covers: